Richard Klausner - 10 Jun 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: Director
Issuer ticker: LYEL
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:21:00 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Meltz, Attorney-in-Fact

Key filing fact

Richard Klausner filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 12 Jun 2026.

Key facts

This page summarizes Richard Klausner's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 16:21.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001591178 Primary reporting owner

Klausner Richard

Relationship: Director
Address: C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO
Signature: /s/ Mark Meltz, Attorney-in-Fact
Signature date: 11 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LYEL holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 148,391
Date: 10 Jun 2026
Ownership: Direct
Footnotes: F1

LYEL holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 42,166
Date: 10 Jun 2026
Ownership: Grantor and Trustee
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYEL transaction Derivative

Option (right to buy)

Award

Transaction value
Shares: +9,250
Change %
Price: $0.000000^*
Shares after: 9,250
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,250
Exercise price: $13.22
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.

Footnote F2

Consists of 7,900 shares held by The Klausner Family Revocable Trust of May 8, 2014, 12,275 shares held by The Ariella Klausner Delaware Trust, 9,716 shares held by The Eli Klausner Delaware Trust and 12,275 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the "Delaware Trusts"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein

Footnote F3

The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.